NASDAQ:ADMA - ADMA Biologics Stock Price, Forecast & News

ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."

ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.04. The biotechnology company had revenue of $7.22 million for the quarter, compared to analyst estimates of $5.71 million. ADMA Biologics had a negative return on equity of 203.21% and a negative net margin of 260.92%. View ADMA Biologics' Earnings History.

ADMA Biologics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for ADMA Biologics.

ADMA Biologics updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $29.2-29.2 million, compared to the consensus revenue estimate of $25.38 million.

6 equities research analysts have issued 12 month target prices for ADMA Biologics' stock. Their forecasts range from $4.00 to $14.00. On average, they anticipate ADMA Biologics' share price to reach $10.20 in the next twelve months. This suggests a possible upside of 148.8% from the stock's current price. View Analyst Price Targets for ADMA Biologics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.

News coverage about ADMA stock has been trending somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ADMA Biologics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the next few days. View News Stories for ADMA Biologics.

ADMA Biologics saw a increase in short interest in December. As of December 13th, there was short interest totalling 5,110,000 shares, an increase of 10.1% from the November 28th total of 4,640,000 shares. Based on an average trading volume of 708,300 shares, the days-to-cover ratio is currently 7.2 days. Currently, 11.3% of the company's shares are short sold. View ADMA Biologics' Current Options Chain.

Some companies that are related to ADMA Biologics include Krystal Biotech (KRYS), BAVARIAN NORDIC/S (BVNRY), Sangamo Therapeutics (SGMO), Proteon Therapeutics (PRTO), Vericel (VCEL), Oyster Point Pharma (OYST), AVITA MED LTD/S (RCEL), Atara Biotherapeutics (ATRA), Adverum Biotechnologies (ADVM), Twist Bioscience (TWST), Cellectis (CLLS), GENFIT S A/ADR (GNFT), MeiraGTx (MGTX), Osiris Therapeutics (OSIR) and AVITA MED LTD/S (AVMXY).

Based on aggregate information from My MarketBeat watchlists, some companies that other ADMA Biologics investors own include Viking Therapeutics (VKTX), Corbus Pharmaceuticals (CRBP), Verastem (VSTM), Gilead Sciences (GILD), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL), Adamis Pharmaceuticals (ADMP), Bellicum Pharmaceuticals (BLCM), Catalyst Pharmaceuticals (CPRX) and Sorrento Therapeutics (SRNE).

ADMA Biologics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include California Public Employees Retirement System (0.15%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Life Sciences Maste Perceptive. View Institutional Ownership Trends for ADMA Biologics.

ADMA stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Life Sciences Maste Perceptive. View Insider Buying and Selling for ADMA Biologics.

Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMA stock can currently be purchased for approximately $4.10.

ADMA Biologics has a market capitalization of $243.21 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.View Additional Information About ADMA Biologics.

The official website for ADMA Biologics is http://www.admabiologics.com/.

ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]